Literature DB >> 21402097

Time course of the attenuation effect of repeated antipsychotic treatment on prepulse inhibition disruption induced by repeated phencyclidine treatment.

Ming Li1, Erik He, Nick Volf.   

Abstract

Antagonism of prepulse inhibition (PPI) deficits produced by psychotomimetic drugs has been widely used as an effective tool for the study of the mechanisms of antipsychotic action and identifying potential antipsychotic drugs. Many studies have relied on the acute effect of a single administration of antipsychotics, whereas patients with schizophrenia are treated chronically with antipsychotic drugs. The clinical relevance of acute antipsychotic effect in this model is still an open question. In this study, we investigated the time course of repeated antipsychotic treatment on persistent PPI deficit induced by repeated phencyclidine (PCP) treatment. After a baseline test with saline, male Sprague-Dawley rats were repeatedly injected with either vehicle, haloperidol (0.05mg/kg), clozapine (5.0 or 10.0mg/kg), olanzapine (2.0mg/kg), risperidone (1.0mg/kg) or quetiapine (10mg/kg), followed by PCP (1.5mg/kg, sc) and tested for PPI once daily for 6 consecutive days. A single injection of PCP disrupted PPI and this effect was maintained with repeated PCP injections throughout the testing period. Acute clozapine, but not other antipsychotic drugs, attenuated acute PCP-induced PPI disruption at both tested doses. With repeated treatment, clozapine and quetiapine maintained their attenuation, while risperidone enhanced its effect with a significant reduction of PCP-induced disruption toward the end of treatment period. In contrast, repeated haloperidol and olanzapine treatments were ineffective. The PPI effects of these drugs were more conspicuous at a higher prepulse level (e.g. 82dB) and were dissociable from their effects on startle response and general activity. Overall, the repeated PCP-PPI model appears to be a useful model for the study of the time-dependent antipsychotic effect, and may help identify potential treatments that have a quicker onset of action than current antipsychotics.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21402097      PMCID: PMC3081992          DOI: 10.1016/j.pbb.2011.03.007

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  47 in total

1.  "Early" and "late" effects of sustained haloperidol on apomorphine- and phencyclidine-induced sensorimotor gating deficits.

Authors:  Z A Martinez; J Oostwegel; M A Geyer; G D Ellison; N R Swerdlow
Journal:  Neuropsychopharmacology       Date:  2000-11       Impact factor: 7.853

2.  Contrasting mechanisms of action and sensitivity to antipsychotics of phencyclidine versus amphetamine: importance of nucleus accumbens 5-HT2A sites for PCP-induced locomotion in the rat.

Authors:  M J Millan; M Brocco; A Gobert; F Joly; K Bervoets; J Rivet; A Newman-Tancredi; V Audinot; S Maurel
Journal:  Eur J Neurosci       Date:  1999-12       Impact factor: 3.386

Review 3.  The "delayed onset" of antipsychotic action--an idea whose time has come and gone.

Authors:  Ofer Agid; Phillip Seeman; Shitij Kapur
Journal:  J Psychiatry Neurosci       Date:  2006-03       Impact factor: 6.186

4.  Distinct neural mechanisms underlying acute and repeated administration of antipsychotic drugs in rat avoidance conditioning.

Authors:  Ming Li; Tao Sun; Chen Zhang; Gang Hu
Journal:  Psychopharmacology (Berl)       Date:  2010-07-10       Impact factor: 4.530

5.  Effects of the 5-HT(6) receptor antagonist, SB-271046, in animal models for schizophrenia.

Authors:  B Pouzet; M Didriksen; J Arnt
Journal:  Pharmacol Biochem Behav       Date:  2002-04       Impact factor: 3.533

6.  Effects of the 5-HT(7) receptor antagonist SB-258741 in animal models for schizophrenia.

Authors:  B Pouzet; M Didriksen; J Arnt
Journal:  Pharmacol Biochem Behav       Date:  2002-04       Impact factor: 3.533

7.  Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended.

Authors:  Stefan Leucht; Raymonde Busch; Johannes Hamann; Werner Kissling; John M Kane
Journal:  Biol Psychiatry       Date:  2005-06-15       Impact factor: 13.382

8.  Effects of acute versus chronic treatment with typical or atypical antipsychotics on d-amphetamine-induced sensorimotor gating deficits in rats.

Authors:  M P Andersen; B Pouzet
Journal:  Psychopharmacology (Berl)       Date:  2001-07       Impact factor: 4.530

Review 9.  Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review.

Authors:  M A Geyer; K Krebs-Thomson; D L Braff; N R Swerdlow
Journal:  Psychopharmacology (Berl)       Date:  2001-07       Impact factor: 4.530

10.  Time course for antipsychotic treatment response in first-episode schizophrenia.

Authors:  Robin Emsley; Jonathan Rabinowitz; Rossella Medori
Journal:  Am J Psychiatry       Date:  2006-04       Impact factor: 19.242

View more
  15 in total

1.  Behavioral and pharmacological validation of an integrated fear-potentiated startle and prepulse inhibition paradigm.

Authors:  Mengjiao Zhang; Ming Li
Journal:  Behav Brain Res       Date:  2016-04-06       Impact factor: 3.332

2.  Neural basis of the potentiated inhibition of repeated haloperidol and clozapine treatment on the phencyclidine-induced hyperlocomotion.

Authors:  Changjiu Zhao; Tao Sun; Ming Li
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2012-03-26       Impact factor: 5.067

3.  Parametric studies of antipsychotic-induced sensitization in the conditioned avoidance response model: roles of number of drug exposure, drug dose, and test-retest interval.

Authors:  Natashia Swalve; Ming Li
Journal:  Behav Pharmacol       Date:  2012-08       Impact factor: 2.293

4.  Repeated effects of the neurotensin receptor agonist PD149163 in three animal tests of antipsychotic activity: assessing for tolerance and cross-tolerance to clozapine.

Authors:  Shinnyi Chou; Collin Davis; Sean Jones; Ming Li
Journal:  Pharmacol Biochem Behav       Date:  2014-11-26       Impact factor: 3.533

5.  Adult response to olanzapine or clozapine treatment is altered by adolescent antipsychotic exposure: a preclinical test in the phencyclidine hyperlocomotion model.

Authors:  Qing Shu; Gang Hu; Ming Li
Journal:  J Psychopharmacol       Date:  2013-11-20       Impact factor: 4.153

6.  Contextual and behavioral control of antipsychotic sensitization induced by haloperidol and olanzapine.

Authors:  Chen Zhang; Ming Li
Journal:  Behav Pharmacol       Date:  2012-02       Impact factor: 2.293

7.  Time-dependence of risperidone and asenapine sensitization and associated D2 receptor mechanism.

Authors:  Jun Gao; Ming Li
Journal:  Behav Brain Res       Date:  2013-10-05       Impact factor: 3.332

8.  Long-term impacts of adolescent risperidone treatment on behavioral responsiveness to olanzapine and clozapine in adulthood.

Authors:  Jing Qiao; Qinglin Zhang; Ming Li
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2013-10-16       Impact factor: 5.067

9.  Olanzapine sensitization and clozapine tolerance: from adolescence to adulthood in the conditioned avoidance response model.

Authors:  Jing Qiao; Hong Li; Ming Li
Journal:  Neuropsychopharmacology       Date:  2012-11-07       Impact factor: 7.853

10.  Effects of repeated quetiapine treatment on conditioned avoidance responding in rats.

Authors:  Jun Gao; Min Feng; Natashia Swalve; Collin Davis; Nan Sui; Ming Li
Journal:  Eur J Pharmacol       Date:  2015-11-14       Impact factor: 4.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.